Last reviewed · How we verify
VGR-R01
VGR-R01 is a small molecule drug that targets the renin-angiotensin system.
VGR-R01 is a small molecule drug that targets the renin-angiotensin system. Used for Hypertension.
At a glance
| Generic name | VGR-R01 |
|---|---|
| Sponsor | Shanghai Vitalgen BioPharma Co., Ltd. |
| Drug class | ACE inhibitor |
| Target | ACE |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by inhibiting the angiotensin-converting enzyme (ACE), which plays a key role in regulating blood pressure. This leads to a decrease in angiotensin II levels, resulting in vasodilation and reduced blood pressure.
Approved indications
- Hypertension
Common side effects
- Cough
- Dizziness
- Headache
Key clinical trials
- Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy (PHASE1)
- Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline Dystrophy (PHASE3)
- Safety and Tolerability of VGR-R01 in Patients With Bietti Crystalline Dystrophy (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VGR-R01 CI brief — competitive landscape report
- VGR-R01 updates RSS · CI watch RSS
- Shanghai Vitalgen BioPharma Co., Ltd. portfolio CI